Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA

• Drug: Etanercept
  
  50 mg etanercept once weekly + methotrexate
• Drug: Etanercept
  
  25mg etanercept once weekly + methotrexate
• Drug: Placebo
  
  Placebo comparator once weekly + methotrexate

• Active Comparator: 1
  
  50mg once weekly + methotrexate
  Intervention: Drug: Etanercept
• Active Comparator: 2
  
  25mg once weekly + methotrexate
  Intervention: Drug: Etanercept
• Placebo Comparator: 3
  
  once weekly + methotrexate
  Intervention: Drug: Placebo

Inclusion criteria:

• Subject has a current DAS28 equal to or less than 3.2.
• Subject is currently receiving treatment with etanercept, either 25 mg twice weekly or 50 mg once weekly, for a minimum of 14 months at baseline
• Subject is currently receiving oral, sc or intramuscular methotrexate once weekly, 7.5 mg/week to 25 mg/week and at a stable dose for a minimum of 4 months at baseline.

Exclusion Criteria:

• Subject has earlier had an attempt of discontinuing etanercept for reasons of remission or low disease activity state.
• Subject has received any disease-modifying anti-rheumatic drug, other than methotrexate, within one month before baseline.
• Subject has had a dose of prednisone (or equivalent) >7.5 mg/day or has received intra-articular, intravenous, intramuscular, or subcutaneous corticosteroid within one month of baseline.